Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy

Int J Urol. 2009 Mar;16(3):337-8. doi: 10.1111/j.1442-2042.2008.02189.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Androgen Antagonists / administration & dosage*
  • Androgen Antagonists / adverse effects
  • Anilides / administration & dosage*
  • Anilides / adverse effects
  • Biopsy, Needle
  • Drug Resistance, Neoplasm
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasm Staging
  • Nitriles / administration & dosage*
  • Nitriles / adverse effects
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Radiotherapy, Conformal
  • Risk Assessment
  • Salvage Therapy*
  • Substance Withdrawal Syndrome / etiology*
  • Substance Withdrawal Syndrome / physiopathology
  • Tosyl Compounds / administration & dosage*
  • Tosyl Compounds / adverse effects
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Anilides
  • Nitriles
  • Tosyl Compounds
  • bicalutamide
  • Prostate-Specific Antigen